6533b831fe1ef96bd1299a7f

RESEARCH PRODUCT

A randomized multicenter trial on a lung ultrasound-guided treatment strategy in patients on chronic hemodialysis with high cardiovascular risk

Thierry HannedoucheGiovanni TripepiOlga BalafaAikaterini PapagianniCarmine ZoccaliRadovan HojsClaudia TorinoRosa SicariLuna GarganiItzchak SlotkiItzchak SlotkiLinda ShavitLinda ShavitAlberto Martínez-castelaoAlexandre SeidowskyFrancesca MallamaciKrzysztof LetachowiczEnrico FiaccadoriDimitrie SiriopolYuri BattagliaZiad A. MassyPatrick RossignolGérard M. LondonFriedo W. DekkerKostas C. SiamopoulosPantelis SarafidisRobert EkartThomas BacheletKitty J. JagerAdrian CovicGiuseppe RegolistiMarie-jeanne Coudert-krierAristeidis StavroulopoulosAndrzej WiecekSarah Seiler-mußlerFabio LizziRocco TripepiDanilo FliserCarolina Polo-torcalMarian KlingerAgata MiskiewiczEugenio Picano

subject

cardiovascular riskmedicine.medical_specialtymedicine.medical_treatmentPopulationlung congestionlaw.inventionKidney FailureRandomized controlled trialRenal DialysisRisk FactorslawMulticenter trialInternal medicineHumansMedicineChronicRisk factorESRDeducationLungUltrasonography InterventionalDialysisUltrasonographylung ultrasoundeducation.field_of_studyInterventionalbusiness.industryHazard ratiochronic kidney failuremedicine.diseaseESRD; cardiovascular risk; chronic kidney failure; heart failure hemodialysis; lung congestion; lung ultrasoundHeart Disease Risk FactorsCardiovascular DiseasesNephrologyHeart failureQuality of LifeKidney Failure ChronicHemodialysisheart failure hemodialysisbusiness

description

Lung congestion is a risk factor for all-cause and cardiovascular mortality in patients on chronic hemodialysis, and its estimation by ultrasound may be useful to guide ultrafiltration and drug therapy in this population. In an international, multi-center randomized controlled trial (NCT02310061) we investigated whether a lung ultrasound-guided treatment strategy improved a composite end point (all-cause death, non-fatal myocardial infarction, decompensated heart failure) vs usual care in patients receiving chronic hemodialysis with high cardiovascular risk. Patient-Reported Outcomes (Depression and the Standard Form 36 Quality of Life Questionnaire, SF36) were assessed as secondary outcomes. A total of 367 patients were enrolled: 183 in the active arm and 180 in the control arm. In the active arm, the pre-dialysis lung scan was used to titrate ultrafiltration during dialysis and drug treatment. Three hundred and seven patients completed the study: 152 in the active arm and 155 in the control arm. During a mean follow-up of 1.49 years, lung congestion was significantly more frequently relieved in the active (78%) than in the control (56%) arm and the intervention was safe. The primary composite end point did not significantly differ between the two study arms (Hazard Ratio 0.88; 95% Confidence Interval: 0.63-1.24). The risk for all-cause and cardiovascular hospitalization and the changes of left ventricular mass and function did not differ among the two groups. A post hoc analysis for recurrent episodes of decompensated heart failure (0.37; 0.15-0.93) and cardiovascular events (0.63; 0.41-0.97) showed a risk reduction for these outcomes in the active arm. There were no differences in patient-reported outcomes between groups. Thus, in patients on chronic hemodialysis with high cardiovascular risk, a treatment strategy guided by lung ultrasound effectively relieved lung congestion but was not more effective than usual care in improving the primary or secondary end points of the trial.

10.1016/j.kint.2021.07.024http://www.scopus.com/inward/record.url?scp=85115173658&partnerID=8YFLogxK